<p>4D Molecular Therapeutics, Inc.（納斯達克代碼：FDMT - 獲取免費報告）在週二的午盤交易中下跌了 5.3%。該公司的股價最低曾達到$10.53，最後交易價為$10.4930。午盤交易期間大約交易了 523,751 股，較平均每日交易量 852,534 股下降了 39%。該股票此前收盤價為$11.08。</p>
<h2>分析師評級調整</h2>
<p>幾位研究分析師對該股票發佈了報告。加拿大皇家銀行在 11 月 11 日的研究報告中將 4D Molecular Therapeutics 的目標價從$26.00 上調至$32.00，並給予該股票 “跑贏大盤” 的評級。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 4D Molecular Therapeutics 的 “賣出（d-）” 評級。Roth Capital 在 8 月 12 日的研究報告中將 4D Molecular Therapeutics 的目標價從$44.00 下調至$38.00，並對該股票給予 “買入” 評級。摩根士丹利在 11 月 7 日的研究報告中將 4D Molecular Therapeutics 的評級從 “減持” 上調至 “持平”。最後，Leerink Partners 在 10 月 31 日的研究報告中重申了 “跑贏大盤” 的評級，並設定了$17.00 的目標價。八位研究分析師對該股票給予了 “買入” 評級，兩位給予了 “持有” 評級，一位給予了 “賣出” 評級。根據 MarketBeat 的數據，該公司目前的共識評級為 “適度買入”，共識目標價為$28.70。</p>
<p><strong>閲讀我們關於 FDMT 的最新報告</strong></p>
<h2>4D Molecular Therapeutics 價格表現</h2>
<p>該股票的 50 日簡單移動平均線為$10.43，200 日簡單移動平均線為$7.13。該公司的市值為 6.0015 億美元，市盈率為-2.79，貝塔值為 2.96。</p>
<p>4D Molecular Therapeutics（納斯達克代碼：FDMT - 獲取免費報告）在 11 月 10 日發佈了季度財報。該公司報告季度每股收益（EPS）為 ($1.01)，超出市場共識預期的 ($1.02) $0.01。4D Molecular Therapeutics 的淨利潤率為-174,314.17%，股本回報率為-47.27%。該公司在本季度的收入為$0.09 百萬，而分析師預期為$0.40 百萬。平均而言，賣方分析師預測 4D Molecular Therapeutics, Inc.在當前年度將發佈-2.84 的每股收益。</p>
<h2>4D Molecular Therapeutics 的內部交易</h2>
<p>在相關消息中，內部人士 Scott Bizily 在 10 月 24 日的交易中出售了 2,678 股該公司的股票。股票以平均價格$12.00 出售，總交易額為$32,136.00。交易完成後，該內部人士直接持有該公司 3,594 股，價值約$43,128。這筆交易代表了他們持股比例的 42.70% 的減少。該交易已在 SEC 的備案中披露，相關信息可在 SEC 網站上查閲。內部人士在上個季度出售了 10,763 股公司股票，價值$109,415。9.60% 的股票由內部人士持有。</p>
<h2>機構投資者對 4D Molecular Therapeutics 的看法</h2>
<p>大型投資者最近增加或減少了對該股票的持股。Wexford Capital LP 在第三季度購買了 4D Molecular Therapeutics 的新頭寸，價值約$41,000。Farther Finance Advisors LLC 在第三季度將其在 4D Molecular Therapeutics 的持股增加了 117.4%。Farther Finance Advisors LLC 現在擁有 4,952 股該公司的股票，價值$43,000，此前在上個季度又購買了 2,674 股。Abich Financial Wealth Management LLC 在第三季度獲得了 4D Molecular Therapeutics 的新頭寸，價值約$80,000。Inscription Capital LLC 在第三季度獲得了 4D Molecular Therapeutics 的新頭寸，價值$94,000。最後，Impact Partnership Wealth LLC 在第三季度購買了 4D Molecular Therapeutics 的新股份，價值$96,000。機構投資者持有該公司 99.27% 的股票。</p>
<h2>4D Molecular Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>4D Molecular Therapeutics, Inc.是一家臨牀階段的生物治療公司，利用其治療性載體進化平台在荷蘭和美國開發基因藥物。該公司開發了一系列基因藥物候選產品，專注於眼科、心臟病學和肺病學三個治療領域。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票而非 4D Molecular Therapeutics</li>
<li>ETF 篩選器：用途和逐步指南</li>
<li>辦公套件價格上漲：微軟的大膽舉措伴隨風險</li>
<li>什麼是特別股息？</li>
<li>IBM 的重大賭注：以 110 億美元收購 AI 神經系統</li>
<li>如何有效使用 MarketBeat 評級篩選器</li>
<li>Carvana 從低點飆升超過 10,000%——現在它進入了標準普爾 500 指數</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 4D Molecular Therapeutics 嗎？</h2>
<p>在你考慮 4D Molecular Therapeutics 之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 4D Molecular Therapeutics 並不在名單上。</p>
<p>雖然 4D Molecular Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

FDMT

<p>4D Molecular Therapeutics (NASDAQ:FDMT) 的股票在午盤交易中下跌了 5.3%，交易量顯著減少。分析師的評級不一，普遍共識為 “適度買入”，目標價為 28.70 美元。該公司報告的季度每股收益為（$1.01），略好於預期。內部交易和機構投資值得注意，內部人士持有 9.60% 的股份</p>

<p>4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) was down 5.3% during mid-day trading on Tuesday . The company traded as low as $10.53 and last traded at $10.4930. Approximately 523,751 shares were traded during mid-day trading, a decline of 39% from the average daily volume of 852,534 shares. The stock had previously closed at $11.08.</p>
<div class="lb-trans"><p>4D Molecular Therapeutics, Inc.（納斯達克代碼：FDMT - 獲取免費報告）在週二的午盤交易中下跌了 5.3%。該公司的股價最低曾達到$10.53，最後交易價為$10.4930。午盤交易期間大約交易了 523,751 股，較平均每日交易量 852,534 股下降了 39%。該股票此前收盤價為$11.08。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級調整</h2>
</div><p>Several research analysts have issued reports on the stock. Royal Bank Of Canada raised their price objective on shares of 4D Molecular Therapeutics from $26.00 to $32.00 and gave the stock an &#34;outperform&#34; rating in a research report on Tuesday, November 11th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, October 8th. Roth Capital decreased their target price on shares of 4D Molecular Therapeutics from $44.00 to $38.00 and set a &#34;buy&#34; rating on the stock in a research report on Tuesday, August 12th. Morgan Stanley raised 4D Molecular Therapeutics from an &#34;underweight&#34; rating to an &#34;equal weight&#34; rating in a research note on Friday, November 7th. Finally, Leerink Partners restated an &#34;outperform&#34; rating and set a $17.00 target price on shares of 4D Molecular Therapeutics in a research report on Friday, October 31st. Eight research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $28.70.</p>
<div class="lb-trans"><p>幾位研究分析師對該股票發佈了報告。加拿大皇家銀行在 11 月 11 日的研究報告中將 4D Molecular Therapeutics 的目標價從$26.00 上調至$32.00，並給予該股票 “跑贏大盤” 的評級。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 4D Molecular Therapeutics 的 “賣出（d-）” 評級。Roth Capital 在 8 月 12 日的研究報告中將 4D Molecular Therapeutics 的目標價從$44.00 下調至$38.00，並對該股票給予 “買入” 評級。摩根士丹利在 11 月 7 日的研究報告中將 4D Molecular Therapeutics 的評級從 “減持” 上調至 “持平”。最後，Leerink Partners 在 10 月 31 日的研究報告中重申了 “跑贏大盤” 的評級，並設定了$17.00 的目標價。八位研究分析師對該股票給予了 “買入” 評級，兩位給予了 “持有” 評級，一位給予了 “賣出” 評級。根據 MarketBeat 的數據，該公司目前的共識評級為 “適度買入”，共識目標價為$28.70。</p>
</div><p><strong>Read Our Latest Report on FDMT</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 FDMT 的最新報告</strong></p>
</div><h2>4D Molecular Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>4D Molecular Therapeutics 價格表現</h2>
</div><p>The stock's fifty day simple moving average is $10.43 and its two-hundred day simple moving average is $7.13. The company has a market capitalization of $600.15 million, a price-to-earnings ratio of -2.79 and a beta of 2.96.</p>
<div class="lb-trans"><p>該股票的 50 日簡單移動平均線為$10.43，200 日簡單移動平均線為$7.13。該公司的市值為 6.0015 億美元，市盈率為-2.79，貝塔值為 2.96。</p>
</div><p>4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its quarterly earnings results on Monday, November 10th. The company reported ($1.01) EPS for the quarter, topping the consensus estimate of ($1.02) by $0.01. 4D Molecular Therapeutics had a negative net margin of 174,314.17% and a negative return on equity of 47.27%. The business had revenue of $0.09 million during the quarter, compared to analyst estimates of $0.40 million. On average, sell-side analysts predict that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current year.</p>
<div class="lb-trans"><p>4D Molecular Therapeutics（納斯達克代碼：FDMT - 獲取免費報告）在 11 月 10 日發佈了季度財報。該公司報告季度每股收益（EPS）為 ($1.01)，超出市場共識預期的 ($1.02) $0.01。4D Molecular Therapeutics 的淨利潤率為-174,314.17%，股本回報率為-47.27%。該公司在本季度的收入為$0.09 百萬，而分析師預期為$0.40 百萬。平均而言，賣方分析師預測 4D Molecular Therapeutics, Inc.在當前年度將發佈-2.84 的每股收益。</p>
</div><h2>Insider Transactions at 4D Molecular Therapeutics</h2>
<div class="lb-trans"><h2>4D Molecular Therapeutics 的內部交易</h2>
</div><p>In related news, insider Scott Bizily sold 2,678 shares of the firm's stock in a transaction that occurred on Friday, October 24th. The shares were sold at an average price of $12.00, for a total transaction of $32,136.00. Following the completion of the sale, the insider directly owned 3,594 shares in the company, valued at approximately $43,128. This trade represents a 42.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders sold 10,763 shares of company stock worth $109,415 over the last quarter. 9.60% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在相關消息中，內部人士 Scott Bizily 在 10 月 24 日的交易中出售了 2,678 股該公司的股票。股票以平均價格$12.00 出售，總交易額為$32,136.00。交易完成後，該內部人士直接持有該公司 3,594 股，價值約$43,128。這筆交易代表了他們持股比例的 42.70% 的減少。該交易已在 SEC 的備案中披露，相關信息可在 SEC 網站上查閲。內部人士在上個季度出售了 10,763 股公司股票，價值$109,415。9.60% 的股票由內部人士持有。</p>
</div><h2>Institutional Investors Weigh In On 4D Molecular Therapeutics</h2>
<div class="lb-trans"><h2>機構投資者對 4D Molecular Therapeutics 的看法</h2>
</div><p>Large investors have recently added to or reduced their stakes in the stock. Wexford Capital LP bought a new position in shares of 4D Molecular Therapeutics during the 3rd quarter worth about $41,000. Farther Finance Advisors LLC lifted its holdings in 4D Molecular Therapeutics by 117.4% during the 3rd quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company's stock valued at $43,000 after purchasing an additional 2,674 shares during the last quarter. Abich Financial Wealth Management LLC acquired a new position in shares of 4D Molecular Therapeutics in the 3rd quarter worth approximately $80,000. Inscription Capital LLC acquired a new position in 4D Molecular Therapeutics in the third quarter worth $94,000. Finally, Impact Partnership Wealth LLC bought a new stake in shares of 4D Molecular Therapeutics during the third quarter worth $96,000. Institutional investors own 99.27% of the company's stock.</p>
<div class="lb-trans"><p>大型投資者最近增加或減少了對該股票的持股。Wexford Capital LP 在第三季度購買了 4D Molecular Therapeutics 的新頭寸，價值約$41,000。Farther Finance Advisors LLC 在第三季度將其在 4D Molecular Therapeutics 的持股增加了 117.4%。Farther Finance Advisors LLC 現在擁有 4,952 股該公司的股票，價值$43,000，此前在上個季度又購買了 2,674 股。Abich Financial Wealth Management LLC 在第三季度獲得了 4D Molecular Therapeutics 的新頭寸，價值約$80,000。Inscription Capital LLC 在第三季度獲得了 4D Molecular Therapeutics 的新頭寸，價值$94,000。最後，Impact Partnership Wealth LLC 在第三季度購買了 4D Molecular Therapeutics 的新股份，價值$96,000。機構投資者持有該公司 99.27% 的股票。</p>
</div><h2>4D Molecular Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>4D Molecular Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.</p>
<div class="lb-trans"><p>4D Molecular Therapeutics, Inc.是一家臨牀階段的生物治療公司，利用其治療性載體進化平台在荷蘭和美國開發基因藥物。該公司開發了一系列基因藥物候選產品，專注於眼科、心臟病學和肺病學三個治療領域。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than 4D Molecular Therapeutics</li>
<li>ETF Screener: Uses and Step-by-Step Guide</li>
<li>Office Suite Gets Pricier: Microsoft’s Bold Move Comes With Risk</li>
<li>What is a Special Dividend?</li>
<li>Big Blue’s Big Bet: IBM Buys AI Nervous System for $11B</li>
<li>How to Effectively Use the MarketBeat Ratings Screener</li>
<li>Carvana Soars Over 10,000% From Lows—Now It’s in the S&amp;P 500</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票而非 4D Molecular Therapeutics</li>
<li>ETF 篩選器：用途和逐步指南</li>
<li>辦公套件價格上漲：微軟的大膽舉措伴隨風險</li>
<li>什麼是特別股息？</li>
<li>IBM 的重大賭注：以 110 億美元收購 AI 神經系統</li>
<li>如何有效使用 MarketBeat 評級篩選器</li>
<li>Carvana 從低點飆升超過 10,000%——現在它進入了標準普爾 500 指數</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in 4D Molecular Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 4D Molecular Therapeutics 嗎？</h2>
</div><p>Before you consider 4D Molecular Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 4D Molecular Therapeutics 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 4D Molecular Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 4D Molecular Therapeutics 並不在名單上。</p>
</div><p>While 4D Molecular Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 4D Molecular Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

4D Molecular Therapeutics (NASDAQ:FDMT) 股價下跌 5.3% - 以下是原因